FDA has approved onabotulinumtoxinA (Botox, Allergan Inc.) injection to prevent headaches in adult patients with chronic migraine. To prevent chronic migraine, onabotulinumtoxinA is injected about every 12 weeks in multiple sites around the head and neck to try to dull future headache symptoms.
FDA has approved acetaminophen injection (Ofirmev, Cadence Pharmaceuticals), the first intravenous formulation of acetaminophen for the management of mild-to-moderate pain, moderate-to severe-pain with adjunctive opioid analgesics, and the reduction of fever.
FDA approved trastuzumab (Herceptin, Genentech) for use in combination with cisplatin and capecitabine or 5-fluorouracil to treat patients with human epidermal growth factor receptor 2-overexpressing metastatic gastric or gastroesophageal junction cancer who have not received prior treatment for metastatic disease.
Dabigatran etexilate (Pradaxa, Boehringer Ingelheim) has received FDA approval for the prevention of stroke and blood clots in patients with atrial fibrillation.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., will launch its new APP Drug Hotline on Wednesday, November 10, 2010.
An updated consensus statement on the management of hypertension among African Americans places significant emphasis on a comprehensive assessment and appropriate risk stratification of individual patients with hypertension, stated a report published online October 4 in Hypertension, HealthDay News reported.
In a new randomized, placebo-controlled clinical trial published in the October 13, 2010 Journal of the American Medical Association, trial investigators demonstrated that the use of buprenorphine implants (Probuphine, Titan Pharmaceuticals) could reduce opioid use over a 24-week study period.
According to the findings of the DECISIONS survey study published in a September/October supplement of Medical Decision Making, Americans frequently find themselves faced with high blood pressure, high cholesterol, and depression medication decisions that they are ill prepared to make.
According to the findings of the DECISIONS survey study published in a September/October supplement of Medical Decision Making, Americans frequently find themselves faced with high blood pressure, high cholesterol, and depression medication decisions that they are ill prepared to make.
Pharmacists speak out about choosing the right antibiotic, prescription drug abuse, and generic acquisition costs.
Lack of patient awareness coupled with ballooning numbers of diabetes cases across the United States have impelled pharmacies and organization to make diabetes care and education a priority.
In late September, presenters at the annual meeting of the Agency for Healthcare Research and Quality reported their phase 1 evaluation findings for the Pharmacy Quality Alliance medication-use demonstration project.
To help provide consumers with some protection against winter ailments, manufacturers have introduced a number of new treatments and preventives for dry lips and cold sores, as well as cold and flu medicines for children.
Jon Roth, who has 20 years' experience in healthcare and healthcare association management, will begin his new role as CEO of the California Pharmacists Association on Nov. 22.
A question was posed to students of a pharmacy ethics class. In every case, the answers given by the students were different from the responses of the practicing pharmacists.
Many community pharmacists do not want to get the influenza vaccination; they don't think they need it, and employer incentives aren't there, a new study reveals.
A survey of new Rx, new generic, and new OTC products
Recreational drug use has evolved over the years and "pharming" - kids lifting pills from the folks' medicine cabinets - is now second only to marijuana use.
A growing body of data supports greater pharmacist involvement in medication safety, said speaker Deb Saine at a recent Pharmacy OneSource webinar.
The pharmacist sitting in the office is interested in squeezing out another penny per prescription. The pharmacist behind the locked gate is interested in going home before midnight. Both cannot happen. A side must be chosen.
Interventions for medication adherence should be multifaceted, speakers told attendees at the recent Pharmacy and Technology Conference in San Diego sponsored by the National Association of Chain Drug Stores.
Ongoing diabetes education facilitated by qualified diabetes educators can reduce healthcare costs and improve health outcomes for those diagnosed with diabetes and those at high risk for the disease.
Kathleen Jaeger's appointment as executive vice president and CEO of the NCPA was announced October 25 at the association's annual Convention and Trade Expo in Philadelphia.
The Office of the Inspector General found that CMS reimbursed plan sponsors $43.3 million for prescription drugs on the market that FDA classifies as less than effective.
A growing body of evidence links use of proton pump inhibitors to increased risk of nosocomial Clostridium difficile infection and other morbidities.
Fewer pharmacists than ever before are devoting their full time to dispensing medication.
As the nation rolls out the new healthcare reform law, the National Association of Chain Drug Stores is urging more recognition for the role of pharmacists in medication adherence.
In a unique partnership, Walgreens, the YMCA, and United Health Group are teaming up on a diabetes prevention and control program.
CMS moved to withdraw provisions of the Medicaid pharmacy reimbursement formula under the AMP model, according to a statement issued by the NACDS and NCPA.
FDA has approved saxagliptin and metformin extended-release (XR) (Kombiglyze XR, AstraZeneca/Bristol-Myers Squibb) tablets for the treatment of type 2 diabetes in adults. Kombiglyze XR is the first and only once-a-day metformin XR plus dipeptidyl peptidase-4 (DPP-4) inhibitor combination tablet offering strong glycemic control across glycosylated hemoglobin levels, fasting plasma glucose, and postprandial glucose.